{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T21:27:59Z","timestamp":1694122079949},"reference-count":8,"publisher":"Walter de Gruyter GmbH","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,10,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec id=\"j_jpm-2016-0190_s_999_w2aab3b7b4b1b6b1aab1c18b1Aa\">\n                  <jats:title id=\"d1389240e11523_w2aab3b7b4b1b6b1aab1c18b1aAa\">Aims:<\/jats:title>\n                  <jats:p>Severe preterm fetal growth restriction (FGR) remote from term is problematic. We aimed to investigate the effect of maternally-administered antithrombin on maternal and neonatal outcomes. A prospective, one-arm, pilot study was performed in 14 women with severe FGR (\u22645<jats:sup>th<\/jats:sup> centile) at &lt;28 weeks of gestation, without hypertensive disorders. Maternal plasma concentrations of soluble Feline McDonough Sarcoma (FMS)-like trypsin kinase-1 (sFlt-1) and placental growth factor (PlGF) were measured and categorized into three groups: group 1; low sFlt-1 and high PlGF, group 2; moderate sFlt-1 and low PlGF, and group 3; high sFlt-1 and low PlGF. Antithrombin was administered for 3 days. The incidence of perinatal mortality, infant morbidity, and the period of pregnancy prolongation were compared.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_jpm-2016-0190_s_998_w2aab3b7b4b1b6b1aab1c18b2Aa\">\n                  <jats:title id=\"d1389240e11534_w2aab3b7b4b1b6b1aab1c18b2aAa\">Results:<\/jats:title>\n                  <jats:p>In group 1 (n=4), their pregnancies were extended for longer periods and the maternal and infant outcomes were good. The prolongation periods were shorter in groups 2 (n=3) and 3 (n=7), which resulted in poor maternal [severe preeclampsia or hemolysis, elevated liver enzymes, and low platelet count (HELLP) syndrome] and infant outcomes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_jpm-2016-0190_s_997_w2aab3b7b4b1b6b1aab1c18b3Aa\">\n                  <jats:title id=\"d1389240e11542_w2aab3b7b4b1b6b1aab1c18b3aAa\">Conclusions:<\/jats:title>\n                  <jats:p>The evaluation of the maternal sFlt-1 and PlGF at 21\u201327 weeks of gestation is useful in the managements of severe FGR. Antithrombin treatment could prolong the pregnancies with low sFlt-1 and high PlGF without negatively affecting maternal or fetal health.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1515\/jpm-2016-0190","type":"journal-article","created":{"date-parts":[[2016,12,4]],"date-time":"2016-12-04T10:02:23Z","timestamp":1480845743000},"page":"837-842","source":"Crossref","is-referenced-by-count":3,"title":["Antithrombin improves the maternal and neonatal outcomes but not the angiogenic factors in extremely growth-restricted fetuses at &lt;28 weeks of gestation"],"prefix":"10.1515","volume":"45","author":[{"given":"Midori","family":"Fujisaki","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology and Center for Perinatal Medicine , University of Miyazaki , Miyazaki City , Miyazaki, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Furuta","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology and Center for Perinatal Medicine , University of Miyazaki , Miyazaki City , Miyazaki, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masanao","family":"Ohhashi","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology and Center for Perinatal Medicine , University of Miyazaki , Miyazaki City , Miyazaki, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seishi","family":"Furukawa","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology and Center for Perinatal Medicine , University of Miyazaki , Miyazaki City , Miyazaki, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Kodama","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology and Center for Perinatal Medicine , University of Miyazaki , Miyazaki City , Miyazaki, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuyuki","family":"Kawagoe","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology and Center for Perinatal Medicine , University of Miyazaki , Miyazaki City , Miyazaki, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Sameshima","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology and Center for Perinatal Medicine , University of Miyazaki , Miyazaki City , Miyazaki, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsuyomu","family":"Ikenoue","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology and Center for Perinatal Medicine , University of Miyazaki , Miyazaki City , Miyazaki, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2016,12,3]]},"reference":[{"key":"2023040100153361345_j_jpm-2016-0190_ref_001_w2aab3b7b4b1b6b1ab1b6b1Aa","doi-asserted-by":"crossref","unstructured":"Sameshima H, Kodama Y, Ikenoue T, Kajiwara Y. Antithrombin improves fetal condition in women with severe pre-eclampsia before 32 weeks of gestation; a randomized, double-blind, placebo-controlled trial. J Obstet Gynecol Res. 2008;34:34\u20139.","DOI":"10.1097\/01.ogx.0000313690.29331.0b"},{"key":"2023040100153361345_j_jpm-2016-0190_ref_002_w2aab3b7b4b1b6b1ab1b6b2Aa","doi-asserted-by":"crossref","unstructured":"Benton SJ, Hu Y, Xie F, Kupfer K, Lee SW, Magee LA, et al. Can placental growth factor in maternal circulation identify fetuses with placental intrauterine growth restriction? Am J Obstet Gynecol. 2012;206:163.e1\u20137.10.1016\/j.ajog.2011.09.019","DOI":"10.1016\/j.ajog.2011.09.019"},{"key":"2023040100153361345_j_jpm-2016-0190_ref_003_w2aab3b7b4b1b6b1ab1b6b3Aa","doi-asserted-by":"crossref","unstructured":"Espinoza J, Romero R, Nien JK, Gomez R, Kusanovic JP, Goncalves LF, et al. Idetification of patients at risk for early onset and\/or severe preeclampsia with the use of uterine artery Doppler velocimetry and placental growth factor. Am J Obstet Gynecol. 2007;196:326.e1\u201313.10.1016\/j.ajog.2006.11.002","DOI":"10.1016\/j.ajog.2006.11.002"},{"key":"2023040100153361345_j_jpm-2016-0190_ref_004_w2aab3b7b4b1b6b1ab1b6b4Aa","doi-asserted-by":"crossref","unstructured":"Kono Y, Yonemoto N, Kusuda S, Hirano S, Iwata O, Tanaka K, et al. Developmental assessment of VLBW infants at 18 months of age: a comparison study between KSPD and Bayley III. Brain Dev. 2016;38:377\u201385.10.1016\/j.braindev.2015.10.01026542468","DOI":"10.1016\/j.braindev.2015.10.010"},{"key":"2023040100153361345_j_jpm-2016-0190_ref_005_w2aab3b7b4b1b6b1ab1b6b5Aa","doi-asserted-by":"crossref","unstructured":"Levine T, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, et al. Circulating angiogenetic factors and the risk of preeclampsia. N Engl J Med. 2004;350:672\u201383.10.1056\/NEJMoa031884","DOI":"10.1056\/NEJMoa031884"},{"key":"2023040100153361345_j_jpm-2016-0190_ref_006_w2aab3b7b4b1b6b1ab1b6b6Aa","doi-asserted-by":"crossref","unstructured":"Moore GS, Allshouse AA, Winn VD, Galan HL, Heyborne KD. Baseline placental growth factor levels for the prediction of benefit from early aspirin prophylaxis for preeclampsia prevention. Pregnancy Hypertens. 2015;5:280\u20136.2659774110.1016\/j.preghy.2015.06.001","DOI":"10.1016\/j.preghy.2015.06.001"},{"key":"2023040100153361345_j_jpm-2016-0190_ref_007_w2aab3b7b4b1b6b1ab1b6b7Aa","doi-asserted-by":"crossref","unstructured":"Widmer M, Cuesta C, Khan KS, Conde-Agudelo A, Carroli G, Fusey S, et al. Accuracy of angiogenic biomarkers at \u226420 weeks\u2019 gestation in predicting the risk of preeclampsia: a WHO multicenter study. Pregnancy Hypertens. 2015;5:330\u20138.10.1016\/j.preghy.2015.09.004","DOI":"10.1016\/j.preghy.2015.09.004"},{"key":"2023040100153361345_j_jpm-2016-0190_ref_008_w2aab3b7b4b1b6b1ab1b6b8Aa","unstructured":"Sato Y, Benirschke K, Marutsuka K, Yano Y, Hatakeyama K, Iwakiri T, et al. Associations of intrauterine growth restriction with placental pathological factors, maternal factors, and fetal factors; cliniclpathological findings of 257 Japanese cases. Histol Histopathol. 2013;28:127\u201332.23233065"}],"container-title":["Journal of Perinatal Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.degruyter.com\/view\/j\/jpme.2017.45.issue-7\/jpm-2016-0190\/jpm-2016-0190.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpm-2016-0190\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpm-2016-0190\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T14:35:27Z","timestamp":1680359727000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpm-2016-0190\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,3]]},"references-count":8,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2017,4,13]]},"published-print":{"date-parts":[[2017,10,26]]}},"alternative-id":["10.1515\/jpm-2016-0190"],"URL":"https:\/\/doi.org\/10.1515\/jpm-2016-0190","relation":{},"ISSN":["1619-3997","0300-5577"],"issn-type":[{"value":"1619-3997","type":"electronic"},{"value":"0300-5577","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12,3]]}}}